WASATCH FUNDS - Curian Clearing
WASATCH FUNDS - Curian Clearing
WASATCH FUNDS - Curian Clearing
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>WASATCH</strong> CORE GROWTH FUND (WGROX / WIGRX) — Management Discussion<br />
MARCH 31, 2015 (UNAUDITED)<br />
The Wasatch Core Growth Fund is managed by a team of<br />
Wasatch portfolio managers led by JB Taylor and Paul Lambert.<br />
JB Taylor<br />
Lead Portfolio Manager<br />
Paul Lambert<br />
Portfolio Manager<br />
OVERVIEW<br />
Small-cap stocks<br />
were strong in the<br />
first quarter of<br />
2015. After a year<br />
of trailing the S&P<br />
500 ® Index, small<br />
caps outperformed<br />
their larger-cap<br />
counterparts for<br />
the second quarter<br />
in a row. It was<br />
also another quarter in which the average small-cap manager<br />
underperformed. In this context, we were pleased that the<br />
Wasatch Core Growth Fund — Investor Class gained 7.30%<br />
and outperformed its benchmarks. The Russell 2000 Index<br />
advanced 4.32% and the Russell 2000 Growth Index<br />
returned 6.63%. We attribute our performance to solid<br />
stock-picking, which was strong across the Fund.<br />
DETAILS OF THE QUARTER<br />
It’s impossible to discuss the current market environment<br />
without addressing the phenomenal performance of the<br />
biotechnology industry. The average biotechnology stock in<br />
the Russell 2000 Growth Index was up approximately 15%<br />
in the quarter, more than double the overall Index return.<br />
This has been an impressive run — in 13 of the last 16 quarters<br />
biotechnology stocks have outperformed.<br />
The Fund’s minimal exposure to biotech companies has<br />
been a huge headwind. Most biotech companies go years<br />
without generating profits, and a company with great science<br />
may still fail to win Food and Drug Administration<br />
approval for its products. More biotech companies will fail<br />
than succeed, and the big winners heavily skew the<br />
industry’s performance.<br />
We want to own profitable companies like Icon plc,<br />
which provides clinical-research services to the biotechnology<br />
industry. We call this a “picks and shovels”<br />
approach — selling goods and services to a well-capitalized<br />
group of risk-takers. In the first quarter, Icon was among<br />
our best contributors.<br />
We will continue to execute our current strategy for the<br />
biotech industry, running a large underweight versus the<br />
benchmark, but occasionally rifle-shooting for a company<br />
with great science, a proven management team and a market<br />
valuation that is small relative to the company’s endmarket<br />
potential.<br />
The U.S. dollar continued to strengthen in the first quarter<br />
and the price of oil is still nearly 50% below the price last<br />
summer. Low-priced oil helps a company like our small-cap<br />
airline Allegiant Travel Co., where fuel is the largest single<br />
cost item in the income statement. Allegiant was the top<br />
contributor to the Fund’s performance in the first quarter.<br />
Although the overall backdrop for small-cap fundamentals<br />
is the best we have seen in a long time, valuations<br />
remain high for U.S. small caps. The number of companies<br />
trading with market valuations greater than 10 times revenues,<br />
a valuation metric we would consider “extreme,”<br />
remains close to an all-time high. A historically low number<br />
of companies today qualify as inexpensive (less than 1 times<br />
revenues). We believe we must stay disciplined with our<br />
valuations in such an elevated market. At quarter-end, the<br />
Fund’s price-to-earnings (P/E) multiple was roughly in line<br />
with both indices, but we have been capturing much betterthan-average<br />
revenue and earnings growth rates.<br />
It’s not customary for us to outperform in such a strong<br />
small-cap market. Our focus on high-quality companies<br />
typically has resulted in the Fund giving up some performance<br />
relative to the indices in the strongest markets, but it<br />
has often outperformed by a wide margin in choppier markets.<br />
To illustrate, on the 100 worst market days between<br />
December 31, 2012 and March 31, 2015, the Russell 2000<br />
Growth Index was down, on average, -1.6%, and the<br />
Wasatch Core Growth Fund outperformed on 92% of those<br />
days. We attribute the Fund’s recent outperformance to the<br />
underlying fundamentals of our portfolio companies. For<br />
example, the Fund’s second-best contributor was Credit<br />
Acceptance Corp., a non-prime auto-finance company that<br />
we believe has an exceptional management team and a track<br />
record for prudently allocating capital.<br />
Life Time Fitness, Inc. and Polypore International, Inc.<br />
announced that they were being acquired. Even though<br />
these two companies were top contributors for the quarter,<br />
we didn’t spend much time cheering. When they have been<br />
acquired, we’ll need to find businesses of comparable<br />
strength to replace them with.<br />
From our first purchase in 2005 through the end of 2012,<br />
MSC Industrial Direct Co., Inc. executed superbly and<br />
continued to take profitable share in a large maintenance,<br />
repair and operations market. Since then, the company has<br />
had a difficult time turning investment spending on new<br />
initiatives into profitable growth.<br />
Cornerstone OnDemand, Inc. posted a solid fourth quarter,<br />
but management gave disappointing guidance. With<br />
30% of Cornerstone’s revenues generated outside the U.S.,<br />
the strong dollar will make the company’s growth rate look<br />
lower in the short term. We like Cornerstone and believe it<br />
is one of the most attractively valued software-as-a-service<br />
(SaaS) businesses in the market.<br />
OUTLOOK<br />
From where we sit, the operating environment for U.S.<br />
small-cap companies continues to improve and the average<br />
U.S. small-cap company’s fundamentals are accelerating.<br />
This has provided a good environment for us to execute<br />
our bottom-up selection process, as we focus on what we<br />
consider to be the highest-quality and best-managed longduration<br />
growth companies. Our companies have<br />
consistently posted revenue and earnings growth rates that<br />
are higher than the average company. The ability to<br />
capture above-average earnings growth, compounded<br />
patiently over time, is at the center of our time-tested<br />
investment philosophy.<br />
Thank you for the opportunity to manage your assets.<br />
Current and future holdings are subject to risk.<br />
4